about
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceSeven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseHigh serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisTesting standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions.International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesInternational staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsHigh-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.The future of autologous stem cell transplantation in myeloma.Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyCYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone diseaseStandard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.Curing myeloma at last: defining criteria and providing the evidence.The molecular classification of multiple myelomaInterleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsA phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsHuman placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bonePatient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.Profile of elotuzumab and its potential in the treatment of multiple myelomaGene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplaHighly activated and expanded natural killer cells for multiple myeloma immunotherapyNAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
P50
Q24610430-06A8EA4D-D16B-474A-A6FE-96D925C660D7Q24651269-3C0DB88A-8810-4489-B602-7FF5AA491B68Q24670135-4500A1EC-7B60-4E98-8D15-110AF1F4465BQ33284138-A6C6BFAA-20D4-4176-939F-58B203DEF03BQ33407570-9C42CF17-8E2A-4336-A0C7-1633CCB7EA59Q33429271-BE865466-0D80-47B0-8299-7DCA9EA81E74Q33438403-771AC46C-A4D2-49AA-9059-DA0DF6AF64D1Q33590961-C95F2757-03CF-4001-8552-DF734039C603Q33710994-4E514E2D-3C1F-4517-91B6-035A3E26B4C5Q33718273-8049333B-EFA9-490C-823C-787859EDC0DFQ33842759-46C66AD9-2883-4CB4-B17E-3E063554C747Q33887470-1C075D95-0A72-4237-8852-C93231DC6CFEQ33917164-E6A41ED0-4E48-408A-835E-0687206B5C0DQ33990944-BBF06C72-BEA3-4B3A-B098-C2A6E2F55E16Q34023078-FDF4C9F2-34B9-4AB7-A364-EE887C0157A4Q34040139-70FBFC09-7EB1-4715-BCF0-0021EE69C176Q34075717-6DFCFC6E-EF2A-4415-A10E-AE970495654BQ34115598-9BE724F2-A629-4BAA-9212-627B0AD666A5Q34122646-7828BCFE-C36A-4B95-99D7-1683AC2F141BQ34292995-D225E492-A67F-4978-A1BE-B0E7B963D889Q34316959-DC6F1536-27C2-45D0-B945-AD57930857C8Q34388367-EAA9702D-94A6-4A1C-B9BC-BA2D9B6B29B1Q34429882-793CF747-2F40-4F77-81F8-79389E782156Q34508313-41376F60-CCFD-43B5-B681-2A252DCDC832Q34530992-8ED7377C-465E-4C51-9A08-30DD6A8A7D59Q34571230-30BC5D78-4B56-4989-87C5-DDF20D051164Q34634446-57DA93F4-E88E-4E49-8363-6249AB7885ADQ35157421-71A88633-42A2-43D4-8ACA-386AF999A799Q35219019-A634854A-C669-4918-87A3-DDCB2FD1A448Q35252771-E3C8904D-7F0E-4887-8111-80E5B772AC90Q35266125-683E3D6F-B06B-485B-88C7-CB2975084FAEQ35610286-807F1C0E-A0E9-444F-9F57-98B759706BA5Q35628678-5E58BA14-2D9A-44D4-AB19-9E28267FB24CQ35628969-DFDE2BD1-8645-483B-8179-28484B61A77BQ35724013-A590A4E8-C502-4A83-B823-CCEABFEEF460Q35848978-176AE5E6-7755-4185-805F-AD7C17C1A011Q36216203-54A1FC43-EFD9-4F4D-8917-0FB7EB0EA432Q36288116-53DF2D6B-62B2-4BA3-8BE0-EF8D3EB94EFBQ36384679-73881AB6-AF45-472C-9196-094145054CC4Q36407085-FD6D53E4-8425-42F9-A9D6-16EC69BF0321
P50
description
onderzoeker
@nl
name
Frits van Rhee
@ast
Frits van Rhee
@en
Frits van Rhee
@es
Frits van Rhee
@nl
Frits van Rhee
@sl
type
label
Frits van Rhee
@ast
Frits van Rhee
@en
Frits van Rhee
@es
Frits van Rhee
@nl
Frits van Rhee
@sl
prefLabel
Frits van Rhee
@ast
Frits van Rhee
@en
Frits van Rhee
@es
Frits van Rhee
@nl
Frits van Rhee
@sl